Delving into the Latest Updates on Omeprazole with Synapse

Overview

Basic Info

SummaryOmeprazole is a proton pump inhibitor (PPI) commonly used to treat gastrointestinal disorders including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. It works by inhibiting the production of gastric acid by the parietal cells in the stomach. Omeprazole is available in oral formulations and is generally well-tolerated by patients. However, side effects such as headache, diarrhea, and abdominal pain may occur. Ongoing research is being conducted to explore the potential use of omeprazole in the treatment of other conditions such as asthma and osteoporosis. Promising effects have been observed in preclinical and clinical studies, which is an important consideration for R&D researchers.

Drug Type

Small molecule drug

Synonyms

Aomeilazuo Changrong Jiaonang, Omeprazole (JP17/USP/INN), Omeprezole

+ [34]

Target

Proton pump

Mechanism

Proton pump inhibitors

Therapeutic Areas

NeoplasmsInfectious DiseasesDigestive System Disorders+ [4]

Active Indication

HeartburnAnastomotic ulcerEsophagitis, Peptic+ [5]

Inactive Indication

AdenocarcinomaAdvanced Malignant Solid NeoplasmAutoimmune Diseases+ [12]

Originator Organization

AstraZeneca PLC

Active Organization

Mitsubishi Tanabe Pharma Corp.Taiyo Pharma Co., Ltd.

AstraZeneca PLC

+ [5]

Inactive Organization

AstraZeneca Pharmaceuticals LP

China National Pharmaceutical Industry Corp. Ltd.

Kadmon Corp. LLC

+ [1]

Drug Highest PhaseApproved

First Approval Date

CN (31 Dec 1988),

Duodenal UlcerGastroesophageal RefluxStomach Ulcer+ [1]

Regulation-

Login to view First Approval Timeline

Structure

Molecular FormulaC17H19N3O3S

InChIKeySUBDBMMJDZJVOS-UHFFFAOYSA-N

CAS Registry73590-58-6

PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers.
The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications.
The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.

Start Date01 Jul 2024

Sponsor / Collaborator

Murdoch Childrens Research Institute

NCT06378398 / RecruitingEarly Phase 1

An Early Phase 1 Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy: The Omeprazole and Aspirin Polyp Prevention Study

This trial will obtain biomarker data on the possible preventive effects of omeprazole and low-dose aspirin in colorectal tissue. Persons who have had 5 or more adenomas, 5 or more serrated polyps, or an incompletely removed adenoma or serrated polyp in the colon or rectum are potentially eligible. Before participating in the study, study staff will explain the study and review the consent form. If you are interested and provide consent, study staff will then confirm your eligibility. Once enrolled, participants will take two 20 mg omeprazole tablets and two 81 mg aspirin tablets each day before the first meal each day for 25-45 days.
The study does involve biopsies of the colorectal tissue before and after taking the study medications. The biopsies are samples of tissue, about the size of a grain of rice, that will be taken from the colon or rectum before and after taking the study medications. This is done during a usual, clinical colonoscopy exam and during one more limited exam, called flexible sigmoidoscopy, that is done for the research study. The flexible sigmoidoscopy requires less preparation. Which procedure comes first depends on what fits best with each participant's clinical scenario. Biopsies of both normal mucosa and polyps (if possible) are collected.

Start Date14 Jun 2024

Sponsor / Collaborator

Rogel Cancer Center: University of Michigan

[+1]

100 Clinical Results associated with Omeprazole

Login to view more data

100 Translational Medicine associated with Omeprazole

Login to view more data

100 Patents (Medical) associated with Omeprazole

Login to view more data

9,006

Literatures (Medical) associated with Omeprazole

31 Dec 2024·Journal of pharmaceutical policy and practice

Article

Author: Lekpittaya, Nantaporn ; Angkanavisul, Jintavee ; Montakantikul, Preecha ; Paiboonvong, Taniya ; Siriudompas, Thanison ; Kocharoen, Sumet

Background:

Drug-related problems (DRPs) are important issues that interfere with therapeutic outcomes and can cause adverse events. Pharmacists play a vital role in identifying and resolving DRPs. This study aimed to determine the characteristics, and severity of DPRs, including clinical pharmacists' interventions.

Method:

A retrospective study was conducted at Ramathibodi Hospital, a tertiary university hospital in Thailand. We collected data from the drug-related problem system and the electronic medical record. Descriptive statistics were performed with Statistical Package for Social Sciences (SPSS) software version 18.0.

Results:

There were 580 patients (20.44%) who had at least one DRP. We classified 1255 DRPs based on Cipolle-Strand-Morley Criteria 2012. The most common DRPs were the need for additional drug therapy (27.09%), followed by dosage too low (26.93%) and dosage too high (22.31%). Anti-infective agents (23.71%) and omeprazole (2.70%) were the most common drug groups and drugs causing DRPs, respectively. The severity of DRPs was mostly categorised to be 'no harm' (95.46%). Almost all of the interventions were completely accepted by physicians (99.12%).

Conclusion:

The most common DRPs were the need for additional drug therapy and dosage adjustment of antimicrobial agents. The clinical pharmacists on wards are effective in preventing and resolving DRPs.

01 May 2024·Atencion primaria

Nuevas herramientas para la revisión de la medicación: PRM en pacientes en tratamiento con inhibidores de la bomba de protones

Article

Author: Gutiérrez-Igual, Salvador ; Montesinos Mezquita, M Carmen ; Martí Rodrigo, Alberto ; Romero Crespo, Isabel ; Lucas-Domínguez, Rut

OBJECTIVE:

To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022.

DESIGN:

Descriptive and retrospective observational study.

MATERIAL AND METHODS:

The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).

RESULTS:

The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.

CONCLUSIONS:

The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.

01 Mar 2024·Naunyn-Schmiedeberg's archives of pharmacology

Article

Author: Neamatallah, Thikryat

Gastric ulcer is one of the most frequent gastrointestinal ailments worldwide. Indomethacin, one of the most potent NSAIDs, suffers undesirable ulcerogenic activity. Caffeic acid phenethyl ester (CAPE) has known health benefits. The current study examined the potential of CAPE to combat indomethacin-induced gastric ulcers in rats. Animals were randomized into 5 groups: control, Indomethacin (50 mg/kg) mg/kg), Indomethacin + CAPE (5 mg/kg/day), Indomethacin + CAPE (10 mg/kg), and Indomethacin + Omeprazole (30 mg/kg). CAPE prevented the rise in ulcer index, attenuated histopathological changes and preserved gastric mucin concentration. CAPE efficiently significantly prevented accumulation of malondialdehude (MDA) and prevented exhaustion of the enzymatic activities of catalase (CAT) and superoxide dismutase (SOD). Further, CAPE prevented the rise in the expression of tumor necrosis factor-α (TNF-α), cyclo-oxygenase-2 (COX-2) and nuclear factor kapp-B (NFκB). This was associated with down-regulation of Bax and up-regulation of Bcl-2 mRNA. Finally, CAPE prevented induced indomethacin-induced decrease in heat shock protein 70 (HSP70) in gastric tissues. In conclusion, CAPE possesses the ability to prevent indomethacin-induced gastric ulcer in rats. This involves, at least partially, antioxidation, anti-inflammation, anti-apoptosis and enhancement of HSP70 expression.

77

News (Medical) associated with Omeprazole

23 May 2024

·www.biospace.com

Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib

54% of TKI-treated CML-patients received a PPI 66% of concomitant prescribing was by a different healthcare provider Crystalline dasatinib Cmax and AUC24 reduced by 96% and 88% respectively STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of marketed drugs for the treatment of cancer announced today the online publication of its abstract titled “Frequency of Comedication of Proton Pump Inhibitors with Crystalline Dasatinib in Chronic Myeloid Leukemia and Effects on TKI-Bioavailability” for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 3rd, 2024 at 9-12 AM, Poster nr. 120 (1). While Tyrosine Kinase Inhibitors (TKI), including dasatinib, have profoundly improved clinical outcomes in patients with chronic myeloid leukemia (CML), the bioavailability and systematic exposure of the crystalline formulation of dasatinib is reduced by comedication with acid reducing agents which may affect the clinical response and comedication with proton pump inhibitors, such as omeprazole, should be avoided (2). The collaborative analysis with Uppsala University and the Karolinska Institute and University Hospital demonstrates that 54% of CML patients identified in the Swedish CML-register were prescribed at least one PPI and 34% of TKI-treated patients were comedicated with a PPI. Of those prescribed a PPI, 66% of the prescriptions were by a different healthcare provider. Further, the presentation provides new information on the bioavailability of crystalline dasatinib when comedicated with a PPI, demonstrating a substantially higher than previously reported impact of PPIs on the bioavailability of crystalline dasatinib, with Cmax and AUC24 being reduced by 96% and 88% respectively. “Consistent absorption and bioavailability of dasatinib are critical for adequate disease control and patient outcomes, this is however often overlooked in clinical practice as our data demonstrates,” said Per Andersson, CEO of Xspray. “To address this important issue, we are on track to launch Dasynoc®, our optimized version of dasatinib, with a Prescription Act Use Fee Amendment date (PDUFA-date) of 31st of July 2024 and the US commercial launch of Dasynoc on 1st September 2024.” The abstract is now available online at References: Dahlén T, Larfors G, Lennernäs H et al. Frequency of Comedication of Proton Pump Inhibitors with Crystalline Dasatinib in Chronic Myeloid Leukemia and Effects on TKI-Bioavailability. American Society of Clinical Oncology, Annual Meeting 2024. Chicago. Abstract 6561. Poster 120. Sprycel® (dasatinib) Tablets for oral use. Labeling, Supplement 27. 02 Aug 2023. . Accessed 22 May 2024. About Xspray Pharma AB Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma’s shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit .

Clinical ResultASCO

01 May 2024

·www.pharmaceutical-technology.com

AstraZeneca admits Covid-19 vaccine may cause blood clots in “very rare” cases

A total of 51 cases of blood clot side effects have been filed in the High Court. Credits: Michael Vi/Shutterstock.com AstraZeneca has been embroiled in a class action lawsuit for its Covid-19 vaccine, admitting that the vaccine may cause incidences of thrombosis with thrombocytopenia syndrome (TTS). As reported by The Telegraph on 28 April, the pharma giant wrote in a legal document submitted to the UK High Court in February, “It is admitted that the AstraZeneca vaccine can, in very rare cases, cause TTS. The causal mechanism is not known.” TTS is known to cause blood clots and low blood platelet counts. A total of 51 cases have been filed in the High Court by victims and their families, with The Telegraph reporting that the plaintiffs are seeking compensation valued at approximately GBP 100m. The vaccine, sold under brand names Covishield and Vaxzevria, has previously been linked to a risk of blood clots. In April 2021, the European Medicines Agency’s (EMA) safety committee reported that a jab of the vaccine was associated with blood clots in the brain, abdomen, and arteries as well as thrombocytopenia. At the time, the EMA and the UK Medicines and Healthcare products Regulatory Agency (MHRA) declared that the benefits of the vaccine outweighed the potential risks and encouraged people to get vaccinated. In a November 2021 press release, AstraZeneca reported that two billion doses of its vaccine were supplied to countries across the world less than 12 months after the first approval. The pharma giant also saw profits from its Covid-19 vaccine for the first time in 2022 and reported that it had delivered approximately 102 million doses of its vaccine through COVAX in Q4 2022. See Also: Azenta gets grant for ice-lined vaccine refrigerator with DC powered compressor CHMP recommends AstraZeneca’s Truqap and Faslodex combo approval AstraZeneca’s admission follows a year of legal battles for the lawsuit that alleges that the vaccine caused death and serious injury in multiple instances. According to The Telegraph , the first case was filed in 2023 when a patient reported that the vaccination left him with a permanent brain injury that developed from a blood clot and a bleed in the brain. As per a 29 April coroner’s report from the UK Courts and Tribunals Judiciary, the death of a 28-year-old patient is the latest case to associate blood clot side effects to AstraZeneca’s vaccine. The report concluded that the patient died from cerebral venous sinus thrombosis and Covid-19 vaccine-induced immune thrombotic thrombocytopenia. This is not the first time in recent months that AstraZeneca has been embattled with lawsuits. In October 2023, the company paid $425m (£352.37m) to settle lawsuits that claimed its heartburn medications, Nexium (esomeprazole) and Prilosec (omeprazole), caused chronic kidney disease.

VaccinePatent InfringementmRNAClinical Result

30 Apr 2024

·www.prnewswire.com

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024. A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at . Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference. A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting . Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy and Systemic Sclerosis. Additionally, Cumberland recently received FDA clearance to proceed directly to a Phase II study for patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website at . SOURCE Cumberland Pharmaceuticals Inc.

Phase 2Drug ApprovalFinancial Statement

100 Deals associated with Omeprazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00455	Omeprazole	A02BC01	DB00338

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Heartburn	US	Dexcel Pharma Technologies Ltd.	05 Jul 2017
gastric ulcer benign	US	AstraZeneca Pharmaceuticals LP	23 Feb 2004
Anastomotic ulcer	JP	Mitsubishi Tanabe Pharma Corp.	18 Jan 1991
Esophagitis, Peptic	JP	Mitsubishi Tanabe Pharma Corp.	18 Jan 1991
Adenocarcinoma	US	AstraZeneca Pharmaceuticals LP	14 Sep 1989
Helicobacter pylori infection	US	AstraZeneca Pharmaceuticals LP	14 Sep 1989
Systemic Mastocytosis	US	AstraZeneca Pharmaceuticals LP	14 Sep 1989
Duodenal Ulcer	CN	AstraZeneca PLC	31 Dec 1988
Gastroesophageal Reflux	CN	AstraZeneca PLC	31 Dec 1988
Stomach Ulcer	CN	AstraZeneca PLC	31 Dec 1988
Zollinger-Ellison Syndrome	CN	AstraZeneca PLC	31 Dec 1988

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Upper gastrointestinal hemorrhage	Phase 3	CN	AstraZeneca PLC	01 Aug 2006
Non-erosive gastro-esophageal reflux disease	Phase 3	JP	AstraZeneca PLC	01 Oct 2003
Non-erosive reflux disease	Phase 3	JP	AstraZeneca PLC	01 Oct 2003
Advanced Malignant Solid Neoplasm	Phase 1	US	AstraZeneca PLC	28 Jun 2021
Advanced Malignant Solid Neoplasm	Phase 1	ES	AstraZeneca PLC	28 Jun 2021
Early gastric cancer	Phase 1	CN	China National Pharmaceutical Industry Corp. Ltd.	13 Jun 2020
Gastrinoma	Phase 1	CN	China National Pharmaceutical Industry Corp. Ltd.	13 Jun 2020
Helicobacter-associated gastritis	Phase 1	CN	China National Pharmaceutical Industry Corp. Ltd.	13 Jun 2020
Marginal Zone B-Cell Lymphoma	Phase 1	CN	China National Pharmaceutical Industry Corp. Ltd.	13 Jun 2020
Purpura, Thrombocytopenic, Idiopathic	Phase 1	CN	China National Pharmaceutical Industry Corp. Ltd.	13 Jun 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03551691 (CTgov)	Phase 2	Exocrine Pancreatic Insufficiency \| Cystic Fibrosis	19	Omeprazole 20mg Capsule (Omeprazole)	xfquaqwptl(qpkqschqpt) = edqtegryqn lxejawstda (vegbliswqm, uwvgabvlwi - agsxumgulu) View more	-	30 Apr 2024
				Placebo oral capsule (Placebo)	xfquaqwptl(qpkqschqpt) = ykddfcfyaq lxejawstda (vegbliswqm, ypzefzhitn - mdbroqsczp) View more
NCT02950259 (P212, CTgov)	Phase 1	Male Breast Neoplasms \| Triple Negative Breast Cancer \| Early Stage Breast Carcinoma	16	Multivitamin+Indomethacin+Omeprazole+CYCLOPHOSPHAMIDE (IRX-2 Regimen -Early Stage Breast Cancer)	rdpdqxnwcx(sthgrihjxc) = bsqlzsyyss knehnifbyf (qxtypdjaen, gduagdbeyr - bzsxwetlci) View more	-	30 Jan 2024
				Multivitamin+Indomethacin+Omeprazole+CYCLOPHOSPHAMIDE (IRX-2 Regimen -Triple Negative Breast Cancer)	rdpdqxnwcx(sthgrihjxc) = qwbpfyveeq knehnifbyf (qxtypdjaen, kbertngvdb - bvavomlmov) View more
NCT05319912 (CTgov)	Phase 1	-	18	ALXN1840 (Treatment A: ALXN1840 (Fasted))	jsmafvunyc(ceyytffgou) = kesfodbajh cdljnqelji (obvojapfmz, ailxejweox - fcueysbqbw) View more	-	02 Aug 2023
				ALXN1840 (Treatment B: ALXN1840 (Fed))	jsmafvunyc(ceyytffgou) = pucxtzhbkv cdljnqelji (obvojapfmz, yxuewptnkk - wvzcbhgadg) View more
NCT05319899 (CTgov)	Phase 1	-	18	ALXN1840 (Treatment A: ALXN1840 (Fasted))	gwmspzqprl(ttdgsmwdaw) = aejyruenbv wsaspzzscf (jnzollaixj, zpdpsznvdg - fhxnjqxcnr) View more	-	01 Aug 2023
				Omeprazole+ALXN1840 (Treatment B: Omeprazole + ALXN1840 (Fasted))	gwmspzqprl(ttdgsmwdaw) = rnoagwapsf wsaspzzscf (jnzollaixj, hqkhvgnquj - kazaudxkoi) View more
NCT05342532 (CTgov)	Phase 4	Helicobacter pylori infection	112	Omeprazole+Amoxicillin (High Dose Dual Therapy)	zmwgjllnjz(cfgdayymsj) = nhlrsquzux zlkcumrdqi (fedkwydprg, mhhkydrjrk - nfqrzvqaby) View more	-	01 Feb 2023
				Omeprazole+Clarithromycin+Amoxicillin (Standard Triple Therapy)	zmwgjllnjz(cfgdayymsj) = pyiwvdnrux zlkcumrdqi (fedkwydprg, pyungevlar - riiamnhgdz) View more
Corporate Publications Manual	Not Applicable	Gastrointestinal Hemorrhage	359	Omeprazole+Sodium Bicarbonate	zzjtlpredn(uarhpfopmj) = yqgulnxqxr fydiubjhch (plmvljlizf )	Positive	30 Aug 2022
				Cimetidine	zzjtlpredn(uarhpfopmj) = hsfsifhkcv fydiubjhch (plmvljlizf )
NCT03530995 (CTgov)	Phase 1	Autoimmune Diseases	73	Belumosudil (Part 1, Period 1: Belumosudil Alone)	mqbugxjsch(ojoiudylgm) = vlvraecmfq cxjexnnchj (nhrmhaoxgv, bsjtpzkqzd - fnxatuajak) View more	-	13 Sep 2021
				Itraconazole+Belumosudil (Part 1, Period 2: Belumosudil + Itraconazole)	mqbugxjsch(ojoiudylgm) = evxznskprk cxjexnnchj (nhrmhaoxgv, uorqslmkzf - zhydntvlkv) View more
HOPE Study (ISTH2021)	Not Applicable	Hemophilia A	34	prophylaxis	jlkavwxizg(hyrpbsqxkw) = xhiydfupix stccawuarj (ehwqqqnrpa )	-	17 Jul 2021
				prophylaxis	jlkavwxizg(hyrpbsqxkw) = ttmnxmkyvl stccawuarj (ehwqqqnrpa )
NCT04198948 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	15	Omeprazole+Gliclazide (Gliclazide + Omeprazole)	hyuouzbdxl(xximcfkatw) = czhyixzbcm xpywhkakzb (ykexpdhntn, ajkjnqgose - qxnbmauoox) View more	-	15 Jul 2021
				Placebo+Gliclazide (Gliclazide + Placebo)	hyuouzbdxl(xximcfkatw) = iplitfowbh xpywhkakzb (ykexpdhntn, qfldigtqpq - jzwygaaizm) View more
NCT01980095 (ERADICATE Hp, Pubmed \| Antibiotics (Basel)) Manual	Phase 3	Helicobacter pylori infection	-	RHB-105	psplhwcxjb(iwcczvhliz) = fvzjbkcsdy obtxxemlna (vcpsixereu )	Positive	09 Oct 2020